Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down

Use of a Label-Free Platform in a preclinical Contract Research Organization Environment
Bookmark and Share


Caliper Life Sciences

Caliper Discovery Alliances & Services (CDAS) is a Contract Research Organization offering comprehensive in vitro and in vivo preclinical contract research services. Their offering is articulated around different platforms including Target Validation with the creation of transgenic animals, Assay Development, Screening, Safety Pharmacology, Biochemical and Functional cell based profiling, Drug Efficacy in disease models and non-invasive small animal Optical Imaging.

NovaScreen Biosciences, now part of CDAS, pioneered receptor profiling studies in the early 1990’s and has established a best in class safety pharmacology platform with a large number of GPCR binding assays. Functional studies are very complementary to affinity-based radioligand assays as they provide very valuable information on the way a drug interacts with a GPCR target.

Using CDAS GPCRFunctional™ programs, you can determine if a drug is an activator or an inhibitor or what its potency and efficacy are for a given GPCR target. Understanding drug functionality is also an important benefit of functional studies and you can for example identify allosteric modulators that are generally difficult to identify using orthosteric ligand-based radioligand binding assays.

Further Information

Related Content

Caliper Life Sciences and IntegenX Enter License Agreement for Microfluidics Patent Portfolio
IntegenX and Caliper Life Sciences announced a license agreement providing IntegenX access to Caliper's microfluidics patent portfolio.
Friday, March 11, 2011
Caliper and Seegene Partner to Provide Innovative Multiplex Molecular Diagnostics Products
Caliper and Seegene partner to deliver innovative diagnostic panels on Caliper's LabChip® Dx platform.
Tuesday, January 18, 2011
Caliper Life Sciences Completes Previously Announced CRi Acquisition
Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of products and services for drug discovery research, announces that it has completed the acquisition of privately-held Cambridge Research & Instrumentation, Inc. (CRi) pursuant to the terms of the merger agreement previously announced on December 9, 2010.
Wednesday, December 22, 2010
Caliper Life Sciences to Acquire Cambridge Research & Instrumentation
Adds Proprietary Multiplexed In Vivo and Tissue Imaging Technology to Caliper's Leading Portfolio of Drug Discovery, Imaging and Diagnostics Solutions.
Friday, December 10, 2010
Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences
Foundation purchases Caliper’s Staccato system to enable high throughput research processes.
Friday, May 29, 2009
Caliper LS Receives $1.1 Million Task Order from the EPA's ToxCast™ Screening Program
This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.
Wednesday, August 20, 2008
Caliper Life Sciences Forms Alliance with Horizon Discovery
CDAS expands offering to include screening for targeted cancer drugs using genetically-defined in-vitro human disease models.
Thursday, April 10, 2008
Caliper LS Awarded National Institute of Environmental Health Services Contract Valued to $7 Million
Caliper Discovery Alliances & Services to develop customized transgenic and knock-out mouse models.
Thursday, October 04, 2007
Caliper Life Sciences Introduces High Throughput RNA Assay for Gene Expression Studies
According to Company, the new assay assures integrity of RNA samples and offers improved throughput and walk-away time.
Thursday, September 13, 2007
Caliper Life Sciences Licenses Monogram Biosciences' Microfluidics Patents
Additional intellectual property portfolio to expand and strengthen Caliper Driven™ licensing program.
Thursday, May 03, 2007
Caliper Life Sciences Awarded EPA Contract
Caliper Discovery Alliances and Services unit will test environmental chemicals under EPA’s ToxCast research program.
Tuesday, April 10, 2007
Caliper Life Sciences Launches Drug Discovery and Development Services Business
Caliper combines in vitro and in vivo services of Novascreen Biosciences and Xenogen Biosciences to form Discovery Alliances & Services.
Tuesday, January 09, 2007
Caliper Life Sciences Closes Multiple LabChip and IVIS Sales at Top Pharma and Biotech Companies
Pfizer, AstraZeneca and Momenta Pharmaceuticals purchase Caliper systems for In Vitro and In Vivo research efforts.
Wednesday, December 13, 2006
Caliper Continues Momentum with Expanded LabChip 3000 Sales
Currently 12 of the top 15 pharmaceutical companies actively use Caliper systems as key tools in their discovery efforts.
Friday, May 26, 2006
Caliper Life Sciences Aids the Sanger Institute's Protein Expression Project
The Wellcome Trust Sanger Institute has purchased the microfluidic-based LabChip® 90 Automated Electrophoresis System to quality control DNA and proteins.
Wednesday, April 05, 2006
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!